Medline (MDLN) – What Are Analysts Saying About This Stock?

Shares of Medline (NASDAQ:MDLN) have received a consensus recommendation of “Moderate Buy” from the twenty-nine analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, twenty-one have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $46.81.

A number of equities research analysts recently weighed in on MDLN shares. Truist Financial reduced their price objective on Medline from $56.00 to $47.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. BTIG Research reaffirmed a “buy” rating and issued a $55.00 target price on shares of Medline in a report on Thursday, August 27th. Royal Bank Of Canada dropped their target price on Medline from $53.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. BMO Capital Markets reiterated an “outperform” rating and issued a $47.00 target price on shares of Medline in a research report on Thursday, August 6th. Finally, William Blair reissued an “outperform” rating on shares of Medline in a research note on Wednesday, September 23rd.

Medline Stock Performance

NASDAQ MDLN opened at $35.96 on Wednesday. The firm’s fifty day moving average price is $34.71 and its two-hundred day moving average price is $38.18. The stock has a market cap of $47.28 billion and a PE ratio of 45.52. Medline has a fifty-two week low of $31.49 and a fifty-two week high of $50.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.61 and a current ratio of 4.33.

Medline (NASDAQ:MDLN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.18. The company had revenue of $7.68 billion for the quarter. On average, equities analysts expect that Medline will post 1.51 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Private Ltd Gic sold 2,570,999 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the transaction, the insider owned 20,231,483 shares in the company, valued at $715,182,924.05. This trade represents a 11.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 10,787,572 shares of company stock valued at $382,784,591 over the last three months. Corporate insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Medline

A number of institutional investors have recently added to or reduced their stakes in the business. Mass General Brigham Inc boosted its holdings in Medline by 167.6% in the first quarter. Mass General Brigham Inc now owns 70,357 shares of the company’s stock valued at $3,131,000 after acquiring an additional 44,063 shares during the last quarter. Cetera Investment Advisers increased its position in Medline by 128.4% during the 1st quarter. Cetera Investment Advisers now owns 52,088 shares of the company’s stock valued at $2,318,000 after purchasing an additional 29,282 shares during the period. Baird Financial Group Inc. increased its position in Medline by 1,151.5% during the 2nd quarter. Baird Financial Group Inc. now owns 379,944 shares of the company’s stock valued at $14,985,000 after purchasing an additional 349,584 shares during the period. WINTON GROUP Ltd raised its holdings in Medline by 1,263.0% during the 2nd quarter. WINTON GROUP Ltd now owns 367,057 shares of the company’s stock worth $14,477,000 after purchasing an additional 340,127 shares during the last quarter. Finally, Andra AP fonden bought a new position in Medline during the 2nd quarter worth approximately $3,180,000.

Medline Company Profile

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.